ArticleMicrosystems & nanoengineering2024
An integrated microfluidic platform for nucleic acid testing.
Article in Microsystems & nanoengineering, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Integrated microfluidic biosensors: shaping the future of quantitative life sciences and on-chip molecular diagnostics.Lab on a chip · 2026Review
- Tumor extracellular vesicle RNA profiling predicts treatment response in pediatric diffuse midline glioma.bioRxiv : the preprint server for biology · 2026Article
- A smartphone-powered decentralized microfluidic platform for sensitive CRISPR-based nucleic acid detection.Microsystems & nanoengineering · 2026Article
- Development of a colorimetric RT-LAMP-based microfluidic device for SARS-CoV-2 detection.Tropical medicine and health · 2026Article
- Paper-Based Microfluidic Chips for At-Home Point-of-Care Nucleic Acid Testing: Applications and Challenges.Diagnostics (Basel, Switzerland) · 2026Review
- Review
- Low-power microfluidic RT-LAMP system with real-time fluorescence detection for portable nucleic acid testing.Mikrochimica acta · 2025Article
- MIDAS: rapid, multiplexed molecular profiling for integrated host-pathogen analysis.Nature communications · 2025Article
- Next-Generation Biomaterials: Design Strategies, Clinical Translation, and the Rise of Intelligent Therapeutic Platforms.ACS omega · 2025Review
- Triple-mode point-of-care diagnostics for high-risk human papillomavirus in urine.Biosensors & bioelectronics: X · 2025Article
- Integrated microfluidic cartridge for rapid and colorimetric detection of Mycoplasma pneumoniae.Mikrochimica acta · 2025Article
- Rapid Amplification and Detection of Single-Stranded Nucleic Acids for Point-of-Care Diagnosis.Small methods · 2025Review
- A rapid and visual dual LAMP-LFD assay for on-site simultaneous detection of influenza A virus (H1N1) and respiratory syncytial virus (RSV).Frontiers in microbiology · 2025Article
- Isothermal nucleic acid amplification for monitoring hand-foot-and-mouth disease: current status and future implications.Mikrochimica acta · 2024Review
- Miniaturized electrophoresis: An integrated microfluidic cartridge with functionalized hydrogel-assisted LAMP for sample-to-answer analysis of nucleic acid.Biomicrofluidics · 2024Article
- Microfluidics chips fabrication techniques comparison.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents a rapid and versatile low-cost sample-to-answer system for SARS-CoV-2 diagnostics. The system integrates the extraction and purification of nucleic acids, followed by amplification via either reverse transcription-quantitative polymerase chain reaction (RT-qPCR) or reverse transcription loop-mediated isothermal amplification (RT-LAMP). By meeting diverse diagnostic and reagent needs, the platform yields testing results that closely align with those of commercial RT-LAMP and RT‒qPCR systems. Notable advantages of our system include its speed and cost-effectiveness. The assay is completed within 28 min, including sample loading (5 min), ribonucleic acid (RNA) extraction (3 min), and RT-LAMP (20 min). The cost of each assay is ≈ $9.5, and this pricing is competitive against that of Food and Drug Administration (FDA)-approved commercial alternatives. Although some RNA loss during on-chip extraction is observed, the platform maintains a potential limit of detection lower than 297 copies. Portability makes the system particularly useful in environments where centralized laboratories are either unavailable or inconveniently located. Another key feature is the platform's versatility, allowing users to choose between RT‒qPCR or RT‒LAMP tests based on specific requirements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.